Enzyme Inhibitors for Breast Cancer Therapy
- Authors: Hariharan Jayaraman, Praveen Kumar Posa Krishnamoorthy2, Lakshmi Suresh, Mahalakshmi Varadan, Aparna Madan, Balu Ranganathan
-
View Affiliations Hide Affiliations2 Department of Biotechnology, Sri Venkateswara College of Engineering, Sriperumbudur Tk. 602 117, Kancheepuram District, Tamil Nadu, India
- Source: Enzyme Inhibition - Environmental and Biomedical Applications , pp 204-227
- Publication Date: August 2020
- Language: English
Enzyme Inhibitors for Breast Cancer Therapy, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789811460821/chapter-11-1.gif
Globally millions of women die of cancer, the most common cancer occurrence sites for women being breast, cervical and ovarian. Engineered enzyme inhibitors are a component of the drug regimen that has taken a drive into pharmaceutical international corporationsÂ’ product portfolios which is by targeted delivery, moderating disease-free survival and leading to procrastination of death. Since 2002 the enzyme inhibitor anastrozole (Arimidex) is used as the first drug of choice for breast cancer which is available in the commercial market. Currently, there are several other FDA approved enzyme inhibitors like sulfonanilide analogs available in the pharmaceutical shelf decreasing aromatase expression and regulating enzyme activity for the treatment and cure of breast cancer.
-
From This Site
/content/books/9789811460821.chapter-11dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
